On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

The Supreme Court on Friday granted the HIV-prevention field a historic win — yet with a major caveat — as it upheld a ...

Labcorp (LH), and Gilead (GILD) rise as Supreme Court upholds right to free preventive care under Obamacare. Read more here.

The high court found that members of a task force that determines what preventive drugs must be covered can be removed at ...

Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...

The Statistical Center for HIV/AIDS Research and Prevention (SCHARP), located at Fred Hutch Cancer Center, is a statistical and data management center (SDMC) dedicated to supporting investigators who ...

What kind of uptake can Gilead Sciences expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

It can take HIV symptoms years to appear—sometimes even longer—after infection. But within a month or two of HIV entering the body, 40% to 90% of people experience symptoms known as acute retroviral ...

Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an antiviral drug for HIV prevention based on his findings.

The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...